作者
Mona O Mohsen, Ina Balke, Simon Zinkhan, Villija Zeltina, Xuelan Liu, Xinyue Chang, Pascal S Krenger, Kevin Plattner, Zahra Gharailoo, AnneCathrine S Vogt, Gilles Augusto, Marianne Zwicker, Salony Roongta, Dominik A Rothen, Romano Josi, Joana J da Costa, Jan M Sobczak, Aleksandra Nonic, LeeAnne Brand, Katja Nuss, Byron Martina, Daniel E Speiser, Thomas Kündig, Gary T Jennings, Senta M Walton, Monique Vogel, Andris Zeltins, Martin F Bachmann
发表日期
2022/1
期刊
Allergy
卷号
77
期号
1
页码范围
243-257
简介
Background
SARSCoV2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lockdowns, wearing masks, and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or adenoviruses, has greatly added to our ability to keep the virus at bay; again, however, in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for longterm control of SARSCoV2 would be inexpensive production at large scale, ability to make multiple booster injections, and longterm stability at 4℃.
Methods
Here, we describe such a vaccine candidate, consisting of the SARSCoV2 receptorbinding motif (RBM) grafted genetically onto the surface of the immunologically …
学术搜索中的文章
MO Mohsen, I Balke, S Zinkhan, V Zeltina, X Liu… - Allergy, 2022